350 related articles for article (PubMed ID: 26222538)
1. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
Chit A; Roiz J; Aballea S
PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538
[TBL] [Abstract][Full Text] [Related]
2. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
Chit A; Roiz J; Briquet B; Greenberg DP
Vaccine; 2015 Jan; 33(5):734-41. PubMed ID: 25444791
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
9. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis.
Sander B; Kwong JC; Bauch CT; Maetzel A; McGeer A; Raboud JM; Krahn M
PLoS Med; 2010 Apr; 7(4):e1000256. PubMed ID: 20386727
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
Gaglani M; Vasudevan A; Raiyani C; Murthy K; Chen W; Reis M; Belongia EA; McLean HQ; Jackson ML; Jackson LA; Zimmerman RK; Nowalk MP; Monto AS; Martin ET; Chung JR; Spencer S; Fry AM; Flannery B
Clin Infect Dis; 2021 Apr; 72(7):1147-1157. PubMed ID: 32006430
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
13. Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.
Warmath CR; Ortega-Sanchez IR; Duca LM; Porter RM; Usher MG; Bresee JS; Lafond KE; Davis WW
Value Health; 2023 May; 26(5):768-779. PubMed ID: 36436790
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
[TBL] [Abstract][Full Text] [Related]
15. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
[TBL] [Abstract][Full Text] [Related]
16. Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand.
Kittikraisak W; Chittaganpitch M; Gregory CJ; Laosiritaworn Y; Thantithaveewat T; Dawood FS; Lindblade KA
Influenza Other Respir Viruses; 2016 May; 10(3):211-9. PubMed ID: 26588892
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
Meier G; Gregg M; Poulsen Nautrup B
J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
[TBL] [Abstract][Full Text] [Related]
20. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.
Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Bresee JS; Fry AM; Jernigan DB
MMWR Recomm Rep; 2017 Aug; 66(2):1-20. PubMed ID: 28841201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
